EDIT vs. PACB

Performance

Risk-Adjusted Performance

Dividends

Drawdowns

Volatility

Financials

EDIT vs. PACB

Last updated Apr 5, 2025

Compare and contrast key facts about Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EDIT or PACB.

Correlation

The correlation between EDIT and PACB is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Correlation: 0.4

Performance

EDIT vs. PACB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). The values are adjusted to include any dividend payments, if applicable.

EDIT

PACB

Key characteristics

Sharpe Ratio

EDIT:

-0.69

PACB:

-0.53

Sortino Ratio

EDIT:

-1.73

PACB:

-0.28

Omega Ratio

EDIT:

0.80

PACB:

0.97

Calmar Ratio

EDIT:

-0.86

PACB:

-0.65

Martin Ratio

EDIT:

-1.51

PACB:

-1.21

Ulcer Index

EDIT:

56.29%

PACB:

52.45%

Daily Std Dev

EDIT:

123.66%

PACB:

120.33%

Max Drawdown

EDIT:

-98.86%

PACB:

-97.79%

Current Drawdown

EDIT:

-98.86%

PACB:

-97.60%

Fundamentals

Market Cap

EDIT:

$85.47M

PACB:

$366.36M

EPS

EDIT:

-$2.88

PACB:

-$1.59

PEG Ratio

EDIT:

0.00

PACB:

-0.17

Total Revenue (TTM)

EDIT:

$31.18M

PACB:

$115.20M

Gross Profit (TTM)

EDIT:

$28.16M

PACB:

$26.00M

EBITDA (TTM)

EDIT:

-$164.01M

PACB:

-$319.24M

Returns By Period

In the year-to-date period, EDIT achieves a -18.90% return, which is significantly higher than PACB's -32.79% return.

EDIT

YTD

-18.90%

-49.76%

-69.53%

-84.88%

5Y*

-44.58%

10Y*

N/A

PACB

YTD

-32.79%

-8.21%

-28.49%

-63.06%

5Y*

-14.26%

10Y*

-14.49%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Symbol name

Risk-Adjusted Performance

EDIT vs. PACB — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT

Overall Rank

Sharpe Ratio Rank

Sortino Ratio Rank

Omega Ratio Rank

Calmar Ratio Rank

Martin Ratio Rank

PACB

Overall Rank

Sharpe Ratio Rank

Sortino Ratio Rank

Omega Ratio Rank

Calmar Ratio Rank

Martin Ratio Rank

The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EDIT vs. PACB - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Sharpe ratio

EDIT: -0.69

PACB: -0.53

Sortino ratio

EDIT: -1.73

PACB: -0.28

Omega ratio

EDIT: 0.80

PACB: 0.97

Calmar ratio

EDIT: -0.86

PACB: -0.65

Martin ratio

EDIT: -1.51

PACB: -1.21

The current EDIT Sharpe Ratio is -0.69, which is lower than the PACB Sharpe Ratio of -0.53. The chart below compares the historical Sharpe Ratios of EDIT and PACB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

EDIT

PACB

Dividends

EDIT vs. PACB - Dividend Comparison

Neither EDIT nor PACB has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EDIT vs. PACB - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.86%, roughly equal to the maximum PACB drawdown of -97.79%. Use the drawdown chart below to compare losses from any high point for EDIT and PACB. For additional features, visit the drawdowns tool.

EDIT

PACB

Volatility

EDIT vs. PACB - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 23.84% compared to Pacific Biosciences of California, Inc. (PACB) at 21.58%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

EDIT

PACB

Financials

EDIT vs. PACB - Financials Comparison

This section allows you to compare key financial metrics between Editas Medicine, Inc. and Pacific Biosciences of California, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Item

Quarterly

Annual

Total Revenue: Total amount of money received from sales and other business activities

Values in USD except per share items

Performance Analysis

Risk Analysis

Optimization

Factor Model

EDIT vs. PACB

Correlation

Performance

EDIT vs. PACB - Performance Comparison

Key characteristics

Fundamentals

Returns By Period

Compare stocks, funds, or ETFs

Risk-Adjusted Performance

EDIT vs. PACB — Risk-Adjusted Performance Rank

EDIT

PACB

EDIT vs. PACB - Risk-Adjusted Performance Comparison

Dividends

EDIT vs. PACB - Dividend Comparison

Drawdowns

EDIT vs. PACB - Drawdown Comparison

Volatility

EDIT vs. PACB - Volatility Comparison

Financials

EDIT vs. PACB - Financials Comparison

Performance Analysis

Risk Analysis

Optimization

Factor Model

Portfolios

Screeners

Community